Semax (Met-Glu-His-Phe-Pro-Gly-Pro) and Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) are structurally distinct synthetic peptides studied for different proposed mechanisms: Semax for interactions with neurotrophic signalling pathways and Selank, a tuftsin-derived heptapeptide, for distinct receptor binding properties. Comparative research using both compounds allows investigators to examine whether their differing structural and mechanistic profiles produce distinguishable or overlapping effects in shared experimental models.

Rodent behavioral and cognitive testing paradigms, alongside molecular markers of neurotrophic signalling (such as BDNF expression) and receptor pathway activation, are standard endpoints for studying this combination's proposed neurological effects, typically compared across single-compound and combined-compound treatment arms relative to vehicle controls.

Both Semax and Selank are short synthetic peptides studied with attention to proteolytic stability in experimental design, since peptide degradation can affect the consistency of dosing and timing in research protocols. Researchers typically account for this through standardized handling, storage, and administration timing documented in their experimental methods.